A surrogate FRAX model for the Kyrgyz Republic.


Journal

Archives of osteoporosis
ISSN: 1862-3514
Titre abrégé: Arch Osteoporos
Pays: England
ID NLM: 101318988

Informations de publication

Date de publication:
06 05 2020
Historique:
received: 28 02 2020
accepted: 27 04 2020
entrez: 8 5 2020
pubmed: 8 5 2020
medline: 1 12 2020
Statut: epublish

Résumé

The hip fracture rates from Kazakhstan were used to create a surrogate FRAX® model for the Kyrgyz Republic. The International Society for Clinical Densitometry and International Osteoporosis Foundation recommend utilizing a surrogate FRAX model, based on the country-specific risk of death, and fracture data based on a country where fracture rates are considered to be representative of the index country. This paper describes a surrogate FRAX model for the Kyrgyz Republic. The FRAX model used the incidence of hip fracture from the neighbouring country of Kazakhstan and the death risk for the Kyrgyz Republic. Compared with the model for Kazakhstan, the surrogate model gave somewhat higher 10-year fracture probabilities for men between 60 and 80 years of age and lower probabilities for men above the age of 80. For women the probabilities were similar up to the age of 75-80 years and then lower. There were very close correlations in fracture probabilities between the surrogate and authentic models (1.00) so that the use of the Kyrgyz model had little impact on the rank order of risk. It was estimated that 2752 hip fractures arose in 2015 in individuals over the age of 50 years in the Kyrgyz Republic, with a predicted increase by 207% to 8435 in 2050. The surrogate FRAX model for the Kyrgyz Republic provides the opportunity to determine fracture probability among the Kyrgyz population and help guide decisions about treatment.

Identifiants

pubmed: 32377964
doi: 10.1007/s11657-020-00743-2
pii: 10.1007/s11657-020-00743-2
pmc: PMC7203583
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

68

Références

Osteoporos Int. 2010 Jan;21(1):35-40
pubmed: 19705047
Osteoporos Int. 1999;10(3):240-7
pubmed: 10525717
Arch Osteoporos. 2018 Apr 17;13(1):42
pubmed: 29666948
J Bone Miner Res. 2014;29(5):1067-73
pubmed: 24243719
J Bone Joint Surg Br. 1998 Mar;80(2):243-8
pubmed: 9546453
Osteoporos Int. 2012 Sep;23(9):2239-56
pubmed: 22419370
Osteoporos Int. 1999;9(1):29-37
pubmed: 10367027
Arch Osteoporos. 2020 Feb 27;15(1):30
pubmed: 32108270
Arch Osteoporos. 2012;7:67-73
pubmed: 23225283
J Bone Miner Res. 2005 Feb;20(2):195-201
pubmed: 15647812
Osteoporos Int. 2014 Oct;25(10):2445-51
pubmed: 24980183
Sci Rep. 2018 Jul 23;8(1):11054
pubmed: 30038288
Arch Osteoporos. 2017 Nov 7;12(1):98
pubmed: 29116417
Osteoporos Int. 1997;7(2):138-44
pubmed: 9166394
Osteoporos Int. 2001;12(5):417-27
pubmed: 11444092
Arch Osteoporos. 2020 Jan 28;15(1):13
pubmed: 31993755
Arch Osteoporos. 2018 Oct 31;13(1):118
pubmed: 30382424
Arch Osteoporos. 2016 Dec;11(1):25
pubmed: 27465509
Osteoporos Int. 2008 Apr;19(4):385-97
pubmed: 18292978
J Clin Densitom. 2011 Jul-Sep;14(3):240-62
pubmed: 21810532

Auteurs

O Lesnyak (O)

Mechnikov North West State Medical University, St. Petersburg, Russia.

A Zakroyeva (A)

Ural State Medical University, Yekaterinburg, Russia.

O Lobanchenko (O)

I.K. Akhunbaev Kyrgyz State Medical Academy, Bishkek, Kyrgyz Republic.

H Johansson (H)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.

E Liu (E)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.

M Lorentzon (M)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia.
Geriatric Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

N C Harvey (NC)

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.

E McCloskey (E)

Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK.

J A Kanis (JA)

Mary McKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia. w.j.pontefract@sheffield.ac.uk.
Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK. w.j.pontefract@sheffield.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH